(35) reported that CRP could activate human peripheral blood mononuclear cells to become tumoricidal in vitro against human astrocytoma (CCF-STTG1), renal carcinoma (CAKI-1), and melanoma (SK-MEL 28) cell lines. Here, CRP is linked to melanoma.